- Home
- QTRX vs ACRS Comparison
QTRX vs ACRS Comparison
Compare QTRX & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTRX
- ACRS
- Stock Information
- Founded
- QTRX 2007
- ACRS 2012
- Country
- QTRX United States
- ACRS United States
- Employees
- QTRX N/A
- ACRS N/A
- Industry
- QTRX Biotechnology: Laboratory Analytical Instruments
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- QTRX Industrials
- ACRS Health Care
- Exchange
- QTRX Nasdaq
- ACRS Nasdaq
- Market Cap
- QTRX 241.2M
- ACRS 198.2M
- IPO Year
- QTRX 2017
- ACRS 2015
- Fundamental
- Price
- QTRX $5.95
- ACRS $2.05
- Analyst Decision
- QTRX Hold
- ACRS Strong Buy
- Analyst Count
- QTRX 4
- ACRS 9
- Target Price
- QTRX $11.75
- ACRS $9.25
- AVG Volume (30 Days)
- QTRX 425.0K
- ACRS 1.1M
- Earning Date
- QTRX 11-11-2025
- ACRS 11-05-2025
- Dividend Yield
- QTRX N/A
- ACRS N/A
- EPS Growth
- QTRX N/A
- ACRS N/A
- EPS
- QTRX N/A
- ACRS N/A
- Revenue
- QTRX $125,784,000.00
- ACRS $16,789,000.00
- Revenue This Year
- QTRX N/A
- ACRS N/A
- Revenue Next Year
- QTRX $37.89
- ACRS $7.02
- P/E Ratio
- QTRX N/A
- ACRS N/A
- Revenue Growth
- QTRX N/A
- ACRS N/A
- 52 Week Low
- QTRX $4.05
- ACRS $1.05
- 52 Week High
- QTRX $15.67
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- QTRX 60.51
- ACRS 60.36
- Support Level
- QTRX $5.60
- ACRS $1.74
- Resistance Level
- QTRX $6.20
- ACRS $1.97
- Average True Range (ATR)
- QTRX 0.33
- ACRS 0.10
- MACD
- QTRX 0.01
- ACRS 0.01
- Stochastic Oscillator
- QTRX 73.44
- ACRS 86.11
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.